Berezin Alexander E
Internal Medicine Department, Medical University of Zaporozhye, Mayakovsky av., 25, Zaporozhye, 69035, Ukraine.
Diabetes Metab Syndr. 2019 Mar-Apr;13(2):995-1003. doi: 10.1016/j.dsx.2019.01.018. Epub 2019 Jan 18.
Type 2 diabetes mellitus (T2DM) remains substantial health problem and one of the most prevalent metabolic diseases worldwide. The impact of T2DM on CV mortality and morbidity is embedded through a nature evolution of the disease and is modulated by numerous risk factors, such as hypertension, obesity, dyslipidemia. There is large body of evidence regarding use of the cardiac biomarkers to risk stratification at higher CV risk individuals who belongs to general population and cohort with established CV disease. Although T2DM patients have higher incidence of cardiac and vascular complications than the general population, whether cardiac biomarkers would be effective to risk stratification of the T2DM is not fully understood. The aim of the review is to summarize our knowledge regarding clinical implementation of cardiac biomarkers in risk assessment for T2DM patients. The role of natriuretic peptides, soluble ST2, galectin-3, growth differentiation factor-15, and cardiac troponins are widely discussed.
2型糖尿病（T2DM）仍然是一个严重的健康问题，也是全球最常见的代谢性疾病之一。T2DM对心血管疾病死亡率和发病率的影响是通过该疾病的自然演变产生的，并受到众多风险因素的调节，如高血压、肥胖、血脂异常。有大量证据表明，在属于普通人群和已确诊心血管疾病队列的高心血管风险个体中，使用心脏生物标志物进行风险分层。尽管T2DM患者发生心脏和血管并发症的发生率高于普通人群，但心脏生物标志物对T2DM患者进行风险分层是否有效尚不完全清楚。本综述的目的是总结我们关于心脏生物标志物在T2DM患者风险评估中的临床应用的知识。利钠肽、可溶性ST2、半乳糖凝集素-3、生长分化因子-15和心肌肌钙蛋白的作用得到了广泛讨论。
